Compare Kinder Morgan Inc (KMI) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs GeneDx Holdings Corp — how do they compare? Kinder Morgan Inc trades at $32.49 (market cap $71.81B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Kinder Morgan Inc is far larger — about 35.5× GeneDx Holdings Corp's market cap, and Kinder Morgan Inc pays a 3.66% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kinder Morgan Inc for 150 Days and GeneDx Holdings Corp for 19 Days on average.
| KMI | WGS | |
|---|---|---|
Market Cap | $71.81B | $2.02B |
Volume | 16,921,908 | 734,640 |
Sector | Energy | Health |
52-Week High | $34.31 | $167.51 |
52-Week Low | $25.84 | $34.51 |
Typical Hold Time | 150 Days | 19 Days |
Enterprise Value | $103.86B | $2.05B |
Dividend Yield | 3.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinder Morgan (KMI) trades at $32.49, up 2.11% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with revenue growth from $15.1B in 2024 to $16.94B in 2025 and net income margin expanding to 19.31%. Recent earnings beats and a $10B project backlog support growth prospects, while analyst consensus targets $37.20 with 47% buy ratings.
KMI presents a compelling investment case with stable fee-based revenues, dividend yield support, and natural gas infrastructure growth. Key risks include energy market volatility and high debt levels ($29.66B long-term). The stock offers upside potential from current levels but requires monitoring of cash flow sustainability and interest rate sensitivity.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
